Heart failure represents a substantial health and economic burden on the US. Despite current treatments, the incidence of heart failure - along with its associated morbidity and mortality - continues to rise. Given these clinical observations, new therapeutic strategies are urgently needed and understanding the molecular mechanisms responsible for stress-induced cardiac hypertrophy and dysfunction will be key to develop the necessary medical therapies. Pathologic cardiac remodeling is mediated by increased synthesis of specific proteins in cardiomyocytes. Although significant progress has been made in understanding the transcriptional changes occurring in the remodeling heart, very little is known about how post-transcriptional events control the synthesis of maladaptive proteins in the stressed myocardium. In this proposal we will examine the role of METTL3-mediated m6A mRNA methylation in the heart as a novel pathway regulating cardiac hypertrophy. We hypothesize that METTL3-dependent mRNA methylation regulates cardiac hypertrophy by favoring the translation of specific pro-hypertrophic mRNAs. For the first time, we will characterize this novel pro-hypertrophic program in the human heart and examine its role in clinically relevant animal models. The achievement of the proposed aims will allow the uncovering of a novel mechanism responsible for post-transcriptional regulation of cardiac hypertrophy with obvious therapeutics ramifications.
|Program type||Innovative Research Grant|
|Effective start/end date||01/01/2017 → 12/31/2018|